Alzheimer's: Mood disorders in late-life may be an early indicator
A new study finds a link between mood disorders in late life and the risk of developing dementia. Hakan & Sophie/Stocksy Late-life mood disorders (LLMDs) are mental health issues that first occur or recur at an older age.
Past research shows that people with an LLMD may be at a higher risk of developing dementia.
A new study found that people with LLMDs have larger amounts of the proteins beta-amyloid and tau in their brains than those with no late-onset mental health issues.
Researchers also found that these abnormal brain protein levels can be detected years before traditional dementia symptoms first appear.
In addition to having an impact on a person's quality of life, past research shows that people with an LLMD may be at a higher risk for developing dementia.
'We often encounter cases in clinical practice where patients who develop mood disorders later in life — after the age of 40 — eventually progress to dementia,' Keisuke Takahata, MD, PhD, chief researcher at the National Institutes for Quantum Science and Technology in Japan, told Medical News Today . '
This has led to the shared clinical impression that such mood disorders may, in some cases, represent early symptoms of neurodegeneration. Previous postmortem brain studies also suggest that depression and dementia that occur in old age share common pathologies. However, the underlying pathophysiological mechanisms [have] remained unclear,' he explained.
Researchers also found that these abnormal brain protein levels can be detected years before traditional dementia symptoms first appear.
For this study, researchers recruited 99 adult study participants — 52 participants had an LLMD over the age of 40, and 47 participants acted as age-matched healthy controls.
Additionally, scientists analyzed brain tissue samples from 208 autopsy cases of various neurodegenerative diseases.
At the study's conclusion, researchers found that about 50% of participants with LLMDs had tau accumulation and 29% had amyloid deposits, versus 15% and 2%, respectively, in the control group.
'It suggests that mood disorders can emerge many years — over seven on average — before the typical symptoms of dementia are recognized. In other words, psychiatric symptoms such as depression or mania may be the first clinical indicators of an ongoing neurodegenerative process. Acknowledging this possibility could help shift the clinical mindset to consider dementia in the differential diagnosis of new-onset mood disorders in older adults.'
— Keisuke Takahata, MD, PhD
Takahata and his team also discovered that these abnormal protein amounts could be detected years before traditional cognitive symptoms appeared, with mood symptoms preceding cognitive or motor symptoms by an average of 7.3 years in autopsy cases.
'This finding highlights that mood symptoms can appear well before the clinical onset of dementia, sometimes by more than seven years,. It suggests that we should consider mood disorders — especially those with late onset — as possible prodromal features of neurodegenerative dementias. This perspective has important implications for earlier diagnosis and proactive monitoring of at-risk individuals.'
— Keisuke Takahata, MD, PhD
'Our results reinforce the emerging paradigm in which diagnoses of Alzheimer's disease (AD) and non-AD tauopathies are increasingly informed by objective molecular markers, rather than relying solely on clinical symptoms,' he continued. 'It also underscores the potential utility of PET biomarkers in identifying at-risk individuals at a much earlier stage — perhaps even before they meet the criteria for mild cognitive impairment.'
'We plan to follow individuals with late-life mood disorders over time using longitudinal PET imaging with both tau and amyloid tracers,' Takahata added. 'This approach will allow us to track the progression of pathological changes and relate them to the emergence of cognitive or neurological symptoms. By doing so, we hope to clarify which patients are truly in a prodromal phase of dementia and which may follow a more stable psychiatric course.'
MNT had the opportunity to speak with Richard A. Bermudes, MD, board certified psychiatrist, associate physician in the School of Medicine Department of Psychiatry and Behavioral Sciences at the University of California, Davis, chief medical officer of BrainsWay, and founder of Empathy MindCare, about this study, who commented the findings both validate what's been seen clinically, and fundamentally reframes late-life depression treatment.
'This isn't just about treating mood symptoms anymore — we're potentially intervening in the earliest stages of neurodegeneration,' Bermudes explained. 'The finding that 50% of late-life mood disorder patients showed tau pathology compared to only 15% of healthy controls means we've been underestimating the stakes.' The importance of early detection and diagnosis
'Early detection transforms everything in neurodegenerative disease, and this study positions mood symptoms as potentially our best early biomarker. By the time we see obvious cognitive decline, we've lost years of intervention opportunity — but if depression or mania after age 40 signals underlying pathology seven-plus years before cognitive symptoms, we have an unprecedented therapeutic window.'
— Richard A. Bermudes, MD
'We need to change clinical practice to embrace comprehensive treatment approaches immediately,' Bermudes added. 'The evidence supports aggressive, multimodal intervention for late-life depression, and we have demonstrated safety and remarkable efficacy in older adults.'
MNT also spoke with Gary Small, MD, chair of psychiatry at Hackensack University Medical Center in New Jersey, about this study.
'Symptoms of mood and neurodegenerative disorders overlap, particularly for older adult. Untreated depression increases the risk for dementia, and patients with Alzheimer's disease and other forms of dementia show a high rate of depression.'
— Gary Small, MD
'These new findings are consistent with previous research showing a link between amyloid and tau accumulation in the brain and mood disorders,' Small said. 'Numerous studies indicate that early detection and intervention is an important strategy for neurodegenerative diseases. It is easier to protect a healthy brain than to attempt to repair neural damage once it becomes extensive.'
'Future studies using amyloid and tau PET as well as other neurodegenerative biomarkers in both mood and cognitive disorders will elucidate early detection and prevention strategies,' he added.
Bipolar
Depression
Alzheimer's / Dementia
Anxiety / Stress
Seniors / Aging
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Independent
18 minutes ago
- The Independent
Edinburgh-based research organisation receives £3.6m for AI health project
An Edinburgh-based research organisation has been awarded £3.6 million from Scottish Enterprise for a project that utilises artificial intelligence (AI) to improve medical scans and faster data analysis. Canon Medical Research Europe's (CMRE) new project will cost around £14 million in total, and is expected to benefit both patients and health services. It is hoped it will lead to AI-based smart solutions automating routine tasks, in turn speeding up patient scanning and allowing consultants to make quicker and better-informed decisions for those receiving treatment for illnesses such as cancer. The funding was announced at a recent meeting with president of CMRE Dr Ken Sutherland, Scottish Government Health Secretary Neil Gray and chief executive of Scottish Enterprise Adrian Gillespie ahead of a health event at Expo 2025 in Osaka, Japan, taking place from June 23-26. The Health Secretary said: ' Scotland has a long-standing reputation for innovation in health and life sciences, and Canon Medical Research Europe exemplifies that strength. 'This investment in AI technology has the potential to transform the way we deliver healthcare by speeding up diagnosis, supporting our clinicians, and ultimately improving outcomes for patients. 'I'm proud to see Scottish expertise leading on such cutting-edge developments and look forward to showcasing this innovation on the world stage at Expo 2025 in Japan.' Dr Sutherland said: 'We have a strong focus on AI and automation with the goal of helping clinicians to diagnose and treat more patients. 'It makes me very proud to think that the innovation we create here in Scotland can benefit the people of Scotland and, through our parent company, the rest of the world.' Mr Gillespie said: 'This cutting-edge research project, led by Dr Sutherland and his team at Canon Medical Research Europe in Edinburgh, has the potential to be transformative for the NHS in Scotland and for health services around the world. 'Scotland's life sciences and healthtech industries deliver life-enhancing benefits to patients, while making an enormous contribution to our economy – the life sciences sector alone contributes almost £10.5 billion annually. 'That is also why we are taking a talented Scottish delegation of healthtech companies to Japan Expo to showcase what Scotland has to offer and to forge new connections that will deliver trade and healthcare opportunities.'
Reuters
2 hours ago
- Reuters
Magnitude 6 earthquake strikes off coast of Hokkaido, Japan, GFZ says
June 21 (Reuters) - A Magnitude 6 earthquake struck off coast of Hokkaido, Japan on Sunday, the German Research Centre for Geosciences (GFZ) said. The quake was at a depth of 10 km (6.21 miles), GFZ said.
Reuters
4 hours ago
- Reuters
China's Sciwind's GLP-1 shows similar weight loss to Novo's Wegovy, study finds
June 21 (Reuters) - Overweight patients given an experimental weight loss drug being developed by China's Sciwind Biosciences lost an average of 10% to 15% of their body weight, roughly in line with results from a similar drug sold by Novo Nordisk ( opens new tab, according to a late-stage study published on Saturday. The drug, called ecnoglutide, belongs to a class of drugs that include Novo's Wegovy called GLP-1 receptor agonists, which work by helping control blood sugar levels and triggering a feeling of fullness. "It's going to be competitive," said Dr. Tricia Tan of Imperial College London, who wrote a piece accompanying the data which appeared in medical journal The Lancet. Tan said additional GLP-1s on the market could potentially drive prices down and improve access globally. "It's great to have competition in the market. It's been extremely frustrating - I work in the National Health Service and patients are not getting access to these drugs." Patients have seen even better results with Eli Lilly's (LLY.N), opens new tab Zepbound, which stimulates GLP-1 as well as a second gut hormone called GIP. More than 20% weight loss was reported in clinical trials. According to the Sciwind Phase 3 study, 499 patients were given 1.2 mg, 1.8 mg or 2.4 mg of ecnoglutide as a subcutaneous injection once weekly for 48 weeks, with 165 patients assigned to receive a placebo. The study was conducted at 36 medical centers across China. The patients who received the 1.2 mg dose lost an average of 9.9% of their body weight after 48 weeks, and those who received the 1.8 mg dose lost an average of 13.3% of their body weight. Patients on the 2.4 mg dose lost an average of 15.4% of their body weight. The patients on placebo lost an average of 0.3% of their body weight over the period. The side-effect profile is not significantly different from the other weight loss drugs. Many of the patients given ecnoglutide experienced decreased appetite and gastrointestinal problems, including diarrhea, nausea and vomiting, the study authors wrote.
